Source comparison
Head-to-head comparison
Property BPC-157 Acetate Penta Deca Peptide Arginate Amino acid sequence 15 amino acids (Gly-Glu-Pro-Pro-Pro...) Identical 15 amino acids Salt form Acetate Arginate (arginine) Gastric acid stability (5 hours) ~2% intact ~95% intact Oral bioavailability Less th
This comparison does not assign a generated winner or score.
- Property
- BPC-157 Acetate
- Penta Deca Peptide Arginate
- Amino acid sequence
- 15 amino acids (Gly-Glu-Pro-Pro-Pro...)
- Identical 15 amino acids
- Salt form
- Acetate
- Arginate (arginine)
- Gastric acid stability (5 hours)
- ~2% intact
- ~95% intact
- Oral bioavailability
- Less than 3%
- Greater than 90% (patent data)
- Injection bioavailability
- ~100%
- Nitric oxide enhancement
- Moderate (via eNOS)
- Enhanced (via eNOS + arginine)
- Compounding legality (US)
- Restricted (FDA Category 2)
- Available through licensed providers
- Available forms
- Primarily injectable, some oral
- Injectable, oral capsules, nasal spray, cream
- Typical daily dose (injectable)
- 200-300 mcg twice daily
- 500 mcg - 1 mg once daily
- Typical daily dose (oral)
- 500-1000 mcg (low absorption)
- 500 mcg (high absorption)
- Cost relative
- Lower per unit
- Higher per unit, but fewer doses needed orally
- The table reveals several important patterns. For injectable use, both formulations deliver essentially identical results because the peptide bypasses the gastrointestinal tract entirely. The bioavailability difference only matters for oral, nasal, and topical routes of administration. Researchers using peptide injections may find the practical differences between the two forms less significant than those using nasal spray peptides or oral capsules.